 | Laurent Magy |
Prominent publications by Laurent Magy
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
[ PUBLICATION ]
Importance: Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities.
Objective: To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity.
Design, Setting, and ...
| Also Ranks for: Clinical Characteristics | multiple sclerosis | covid19 severity | patients age | independent risk factors |
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
[ PUBLICATION ]
OBJECTIVE: In this study, we compared the effectiveness of teriflunomide (TRF) and dimethyl fumarate (DMF) on both clinical and MRI outcomes in patients followed prospectively in the Observatoire Français de la Sclérose en Plaques.
METHODS: A total of 1,770 patients with relapsing-remitting multiple sclerosis (RRMS) (713 on TRF and 1,057 on DMF) with an available baseline brain MRI were included in intention to treat. The 1- and 2-year postinitiation outcomes were relapses, increase of ...
| Also Ranks for: Dimethyl Fumarate | trf dmf | comparative effectiveness | multiple sclerosis | patients rrms |
OBJECTIVE: To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French follow-up cohort Observatoire of Multiple Sclerosis.
METHODS: Patients with RRMS included in the study were aged from 18 to 65 years with an Expanded Disability Status Scale score of 0-5.5 and an available brain MRI performed within the year before treatment initiation. The data ...
| Also Ranks for: Natalizumab Fingolimod | patients rrms | year treatment | comparative efficacy | new lesions |
OBJECTIVE: To assess disease activity within 12 months after natalizumab (NZ) discontinuation in a large French postmarketing cohort.
METHODS: In France, patients exposed at least once to NZ were included in the TYSEDMUS observational and multicenter cohort, part of the French NZ Risk Management Plan. Clinical disease activity during the year following NZ discontinuation was assessed in this cohort. Time to first relapse after NZ stop was analyzed using Kaplan-Meier method and ...
| Also Ranks for: Natalizumab Withdrawal | patients nz | multiple sclerosis | 12 months | clinical disease activity |
Upper limb onset of hereditary transthyretin amyloidosis is common in non‐endemic areas
[ PUBLICATION ]
BACKGROUND AND PURPOSE: The aim is to describe an uncommon phenotype of hereditary ATTR neuropathy with upper limb onset.
METHODS: The French TTR Familial Amyloid Polyneuropathy database was used for a retrospective evaluation of 32 consecutive patients with upper limb onset of the neuropathy (study group) and they were compared to 31 Portuguese early-onset patients and 99 late-onset patients without upper limb onset.
RESULTS: Initial upper limb symptoms were mostly sensory. Lower limb ...
| Also Ranks for: Upper Limb | hereditary transthyretin | amyloid neuropathies | onset patients | 3 years |
Laurent Magy: Influence Statistics
| Concept | World rank |
|---|---|
| dmf clinical effectiveness | #24 |
| patients dmftreated patients | #24 |
| trf dimethyl fumarate | #24 |
| rrms trf | #24 |
| dmftreated patients relapses | #24 |
| 2 years dmf | #25 |
| effectiveness teriflunomide | #30 |
| outcomes dmf | #38 |
| natalizumab nz | #40 |
| treatment trf | #40 |
| trf dimethyl | #42 |
| treatment discontinuation lack | #43 |
| compared trf | #43 |
| teriflunomide trf | #46 |
| dmf trf | #54 |
| trf dmf | #54 |
| patients trf | #59 |
| trf treated | #60 |
| trf compared | #62 |
| dmt higher | #64 |
| effectiveness dmf | #72 |
| association dmts | #75 |
| lower dmf | #76 |
| patients nz | #89 |
| dmf clinical | #92 |
| compared dmf | #95 |
| dmftreated patients | #95 |
| relapses increase | #96 |
Key People For Dimethyl Fumarate
Laurent Magy:Expert Impact
Concepts for whichLaurent Magyhas direct influence:Dimethyl fumarate, Multiple sclerosis, Natalizumab fingolimod, Fingolimod natalizumab, Trf dmf, Dmf trf, Patients rrms, Covid19 severity.
Laurent Magy:KOL impact
Concepts related to the work of other authors for whichfor which Laurent Magy has influence:Multiple sclerosis, Dimethyl fumarate, Natalizumab fingolimod, Cladribine tablets, Sarscov2 infection, Covid19 vaccination, Neurological disorders.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |